Literature DB >> 21822789

No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes.

D Iafusco, C Bizzarri, F Cadario, R Pesavento, G Tonini, S Tumini, V Cauvin, C Colombo, R Bonfanti, F Barbetti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21822789     DOI： 10.1007/s00125-011-2273-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  10 in total

1.  UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

Authors:  D R Matthews; C A Cull; I M Stratton; R R Holman; R C Turner
Journal:  Diabet Med       Date:  1998-04       Impact factor: 4.359

2.  Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.

Authors:  G Tonini; C Bizzarri; R Bonfanti; M Vanelli; F Cerutti; E Faleschini; F Meschi; F Prisco; E Ciacco; M Cappa; C Torelli; V Cauvin; S Tumini; D Iafusco; F Barbetti
Journal:  Diabetologia       Date:  2006-07-01       Impact factor: 10.122

3.  Long-term response to sulfonylurea in a patient with diabetes due to mutation in the KCNJ11 gene.

Authors:  Marcio F Vendramini; Lucimary C Gurgel; Regina S Moisés
Journal:  Arq Bras Endocrinol Metabol       Date:  2010-11

4.  Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.

Authors:  Ewan R Pearson; Isabelle Flechtner; Pål R Njølstad; Maciej T Malecki; Sarah E Flanagan; Brian Larkin; Frances M Ashcroft; Iwar Klimes; Ethel Codner; Violeta Iotova; Annabelle S Slingerland; Julian Shield; Jean-Jacques Robert; Jens J Holst; Penny M Clark; Sian Ellard; Oddmund Søvik; Michel Polak; Andrew T Hattersley
Journal:  N Engl J Med       Date:  2006-08-03       Impact factor: 91.245

5.  Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up.

Authors:  Tomasz Klupa; Jan Skupien; Barbara Mirkiewicz-Sieradzka; Agnieszka Gach; Anna Noczynska; Agnieszka Zubkiewicz-Kucharska; Mieczyslaw Szalecki; Elzbieta Kozek; Joanna Nazim; Wojciech Mlynarski; Maciej T Malecki
Journal:  Diabetes Technol Ther       Date:  2010-05       Impact factor: 6.118

6.  Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.

Authors:  Julia Kirchheiner; Jürgen Brockmöller; Ingolf Meineke; Steffen Bauer; Wolfgang Rohde; Christian Meisel; Ivar Roots
Journal:  Clin Pharmacol Ther       Date:  2002-04       Impact factor: 6.875

7.  The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy.

Authors:  Joseph C Koster; Francesco Cadario; Cinzia Peruzzi; Carlo Colombo; Colin G Nichols; Fabrizio Barbetti
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

8.  Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations.

Authors:  Meena Rafiq; Sarah E Flanagan; Ann-Marie Patch; Beverley M Shields; Sian Ellard; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2007-11-19       Impact factor: 19.112

9.  A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.

Authors:  K Shimomura; F Hörster; H de Wet; S E Flanagan; S Ellard; A T Hattersley; N I Wolf; F Ashcroft; F Ebinger
Journal:  Neurology       Date:  2007-07-25       Impact factor: 9.910

10.  Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells.

Authors:  Maria Sara Remedi; Colin G Nichols
Journal:  PLoS Med       Date:  2008-10-28       Impact factor: 11.069
  10 in total
  15 in total

1.  Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes.

Authors:  Brian W Thurber; David Carmody; Elizabeth C Tadie; Ashley N Pastore; Jazzmyne T Dickens; Kristen E Wroblewski; Rochelle N Naylor; Louis H Philipson; Siri Atma W Greeley
Journal:  Diabetologia       Date:  2015-04-17       Impact factor: 10.122

2.  Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons.

Authors:  David Carmody; Charles D Bell; Jessica L Hwang; Jazzmyne T Dickens; Daniela I Sima; Dania L Felipe; Carrie A Zimmer; Ajuah O Davis; Kateryna Kotlyarevska; Rochelle N Naylor; Louis H Philipson; Siri Atma W Greeley
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

Review 3.  Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment.

Authors:  Siri Atma W Greeley; Rochelle N Naylor; Louis H Philipson; Graeme I Bell
Journal:  Curr Diab Rep       Date:  2011-12       Impact factor: 4.810

Review 4.  Precision Medicine: Long-Term Treatment with Sulfonylureas in Patients with Neonatal Diabetes Due to KCNJ11 Mutations.

Authors:  Lisa R Letourneau; Siri Atma W Greeley
Journal:  Curr Diab Rep       Date:  2019-06-27       Impact factor: 4.810

5.  Glyburide ameliorates motor coordination and glucose homeostasis in a child with diabetes associated with the KCNJ11/S225T, del226-232 mutation.

Authors:  Domenica Battaglia; Yu-Wen Lin; Claudia Brogna; Antonino Crinò; Valeria Grasso; Alessia F Mozzi; Lucia Russo; Sabrina Spera; Carlo Colombo; Stefano Ricci; Colin G Nichols; Eugenio Mercuri; Fabrizio Barbetti
Journal:  Pediatr Diabetes       Date:  2012-06-14       Impact factor: 4.866

Review 6.  Glycemic control indicators in patients with neonatal diabetes mellitus.

Authors:  Shigeru Suzuki; Masafumi Koga
Journal:  World J Diabetes       Date:  2014-04-15

Review 7.  Diabetes mellitus and the β cell: the last ten years.

Authors:  Frances M Ashcroft; Patrik Rorsman
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

8.  Permanent neonatal diabetes mellitus: same mutation, different glycemic control with sulfonylurea therapy on long-term follow-up.

Authors:  Banu Kücükemre Aydin; Rüveyde Bundak; Firdevs Baş; Hülya Maraş; Nurçin Saka; Hülya Günöz; Feyza Darendeliler
Journal:  J Clin Res Pediatr Endocrinol       Date:  2012-06

9.  Whole-exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene.

Authors:  Amélie Bonnefond; Julien Philippe; Emmanuelle Durand; Aurélie Dechaume; Marlène Huyvaert; Louise Montagne; Michel Marre; Beverley Balkau; Isabelle Fajardy; Anne Vambergue; Vincent Vatin; Jérôme Delplanque; David Le Guilcher; Franck De Graeve; Cécile Lecoeur; Olivier Sand; Martine Vaxillaire; Philippe Froguel
Journal:  PLoS One       Date:  2012-06-11       Impact factor: 3.240

Review 10.  K(ATP) channels and islet hormone secretion: new insights and controversies.

Authors:  Frances M Ashcroft; Patrik Rorsman
Journal:  Nat Rev Endocrinol       Date:  2013-09-17       Impact factor: 43.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.